Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study
Document Type
Conference Proceeding
Publication Date
1-27-2025
Publication Title
Journal of Clinical Oncology (2025) 43 Supplement 4. Date of Publication: 1 Feb 2025
Abstract
2025 ASCO Gastrointestinal Cancers Symposium, January 23 - 25, 2025, San Francisco, CA
Volume
43
Recommended Citation
Fountzilas, C.; Ko, A.H.; Borazanci, E.H.; D'Olimpio, J.T.; Hecht, J.R.; Tang, Shou-Ching; Shields, A.F.; Salkeni, M.A.; Michelson, G.C.; Liganor, L.; Cho, G.; Cho, S.A.; and Walker, E.J., "Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study" (2025). School of Medicine Faculty Publications. 3710.
https://digitalscholar.lsuhsc.edu/som_facpubs/3710
10.1200/JCO.2025.43.4_suppl.742
Comments
Abstract 742